Bioton S.A. — Investor Relations & Filings
Bioton S.A. is a biotechnology company focused on providing comprehensive solutions for diabetes care. The company's core activity is the development and production of recombinant human insulin, positioning it as a significant commercial manufacturer globally. Its operations cover the full biotechnological process, from DNA research and development to the manufacturing and marketing of finished medicinal products. The product portfolio is centered on various forms of insulin and is complemented by modern automatic injection systems designed to facilitate effective diabetes treatment for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Sprawozdanie z badania SSF | 2026-04-29 | Polish | |
| Sprawozdanie z badania SSF | 2026-04-29 | Polish | |
| Oświadczenie Rady Nadzorczej - Komitet Audytu | 2026-04-29 | Polish | |
| Ocena rocznych sprawozdań dokonana przez Radę Nadzorczą | 2026-04-29 | Polish | |
| List Zarządu do Akcjonariuszy | 2026-04-29 | Polish | |
| List Zarządu do Akcjonariuszy | 2026-04-29 | Polish |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 38668010 | Sprawozdanie z badania SSF | 2026-04-29 | Polish | ||
| 38668005 | Sprawozdanie z badania SSF | 2026-04-29 | Polish | ||
| 38667992 | Oświadczenie Rady Nadzorczej - Komitet Audytu | 2026-04-29 | Polish | ||
| 38667988 | Ocena rocznych sprawozdań dokonana przez Radę Nadzorczą | 2026-04-29 | Polish | ||
| 38667983 | List Zarządu do Akcjonariuszy | 2026-04-29 | Polish | ||
| 38667979 | List Zarządu do Akcjonariuszy | 2026-04-29 | Polish | ||
| 38667976 | Informacja Zarządu - wybór firmy audytorskiej | 2026-04-29 | Polish | ||
| 38667968 | Informacja Zarządu - wybór firmy audytorskiej | 2026-04-29 | Polish | ||
| 38667960 | GK Raport Roczny 2025 | 2026-04-29 | Polish | ||
| 38667956 | GK Raport Roczny 2025 | 2026-04-29 | Polish | ||
| 38667946 | Skonsolidowane sprawozdanie finansowe | 2026-04-29 | Polish | ||
| 38667942 | Skonsolidowane sprawozdanie finansowe | 2026-04-29 | Polish | ||
| 38668606 | Sprawozdanie z badania JSF | 2026-04-29 | Polish | ||
| 38668595 | Sprawozdanie z badania JSF | 2026-04-29 | Polish | ||
| 38668590 | Oświadczenie Rady Nadzorczej - Komitet Audytu | 2026-04-29 | Polish | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Bioton S.A., but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Centessa Pharmaceuticals plc
Clinical-stage pharmaceutical company developing medicines …
|
CNTA | GB | Manufacturing |
|
Century Therapeutics, Inc.
Develops iPSC-derived allogeneic cell therapies for cancer …
|
IPSC | US | Manufacturing |
|
Cereno Scientific AB
Clinical-stage biotech developing drugs for rare cardiovasc…
|
CRNO | SE | Manufacturing |
|
CERO THERAPEUTICS HOLDINGS, INC.
Immunotherapy company developing engineered T cell therapeu…
|
CERO | US | Manufacturing |
|
CERUS CORP
Develops pathogen inactivation technology to reduce transfu…
|
CERS | US | Manufacturing |
|
Cessatech A/S
A biotech company developing medicines for children's acute…
|
CESSA | DK | Manufacturing |
|
CF PharmTech
Develops and manufactures inhalation drugs and delivery sys…
|
2652 | CN | Manufacturing |
|
CF PharmTech, Inc.
Specialty pharmaceutical company developing complex inhalat…
|
2652 | HK | Manufacturing |
|
CG Invites Co., Ltd.
A biopharmaceutical company specializing in digital genomic…
|
083790 | KR | Manufacturing |
|
CG Oncology, Inc.
Develops bladder-sparing oncolytic immunotherapies for urol…
|
CGON | US | Manufacturing |
Bioton S.A. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/5538/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=5538 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=5538 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=5538 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 5538}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bioton S.A. (id: 5538)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.